BMJ  2004;328:1447-1448 (19 June), doi:10.1136/bmj.328.7454.1447

Editorial

Treatment of leprosy

The evidence base for newer drug combinations and shorter regimens is weak

The first 150 words of the full text of this article appear below.

Leprosy still poses major therapeutic challenges. We have effective antibiotics to cure the infection, but the immune mediated peripheral nerve damage can continue long after effective antimicrobial treatment has started, and patients continue to be stigmatised. Effective management should therefore include treatment of nerve damage and reactions, prevention of disability, and reduction of stigma. The regimens recommended by the World Health Organization of six or 24 months' multidrug treatment (rifampicin, dapsone, and clofazimine) produce good clinical responses and low rates of relapse. The long term outcome for shorter regimens and other drug combinations, however, is not known. Testing for recent nerve damage and treating it with steroids is essential. Dermatologists already have an important role in treating patients in the large Indian and Brazilian cities, and this is likely to increase as leprosy programmes are integrated into primary care.

The WHO recommended multidrug regimen of rifampicin, clofazimine, and dapsone has . . . [Full text of this article]

Diana N J Lockwood, consultant leprologist

Hospital for Tropical Diseases, London WC1E 6AU (diana.lockwood@lshtm.ac.uk)

Bhushan Kumar, professor of dermatology

Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (kumarbhushan@hotmail.com)


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Articles

Steroids do not prevent long term nerve damage in leprosy
BMJ 2004 328: 0. [Full Text] [PDF]

Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1)
W Cairns S Smith, Alison M Anderson, Stephen G Withington, Wim H van Brakel, Richard P Croft, Peter G Nicholls, and Jan Hendrik Richardus
BMJ 2004 328: 1459. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

  • Gill, A.L., Bell, D.R., Gill, G.V., Wyatt, G.B., Beeching, N.J. (2005). Leprosy in Britain: 50 years experience in Liverpool. QJM 98: 505-511 [Abstract] [Full text]  

Rapid Responses:

Read all Rapid Responses

A preliminary Study report on Placental Umbilical cord blood transfusion in victims of anemia with Leprosy in Underresourced regions of the World
Niranjan Bhattacharya DSc, MBBS, MD, MS, FACS(USA), et al.
bmj.com, 22 Jun 2004 [Full text]



Access jobs at BMJ Careers
Whats new online at Student 

BMJ